I don't think there were too many mistakes on the part of...

I don't think there were too many mistakes on the part of management, because it's a cash-burning area, and if you put it in the U.S., it will raise more money, and of course the U.S. valuation will be higher. I think the culprits should be the junk hedge funds in Australia, led by regal and platinum, who are constantly shorting and controlling the share price so that they can get cheap chips in the next capital raising, and they have destroyed the value of Australian companies, and the valuation of Australian biotechs is far smaller than anywhere else in the world. These junk hedge funds in Australia have actually helped a lot of foreign capital to acquire a lot of high-quality assets at low prices.